secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2021-08-30T23:59:59+00:00
Accession:  0001104659-21-110678
Event type: m_and_a
Sentiment:  positive
Materiality: 0.95
Item codes: 1.01, 2.01, 5.06, 9.01, 5.02, 3.02, 4.01, 3.03, 5.01, 5.03, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte completes SPAC merger; begins trading as HUMA; $175M PIPE investment closed
--------------------------------------------------------------------------------

- Business combination closed Aug 26, 2021; Legacy Humacyte becomes wholly owned subsidiary Humacyte Global, Inc.
- PIPE investors purchased 17.5M shares at $10.00/share for aggregate $175M; shares issued pre-effective time.
- Exchange ratio: 0.26260 new Humacyte shares per Legacy Humacyte common share; options/warrants adjusted similarly.
- One-year lock-up on most shares; early release if stock hits $15 for 20 of 30 days after 180 days.
- Company plans BLA submission for vascular trauma in 2022, AV access in 2023; ~435 patients implanted as of May 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/0001104659-21-110678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465921110678/tm2126013d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-110678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer